Related Experiment Video
Updated: Jan 8, 2026

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
Published on: February 17, 2023
Rectal Swab Screening as a Predictor of Bacteremia by Multidrug-resistant Microorganisms in Children With
Diego Medina Valencia1,2, Alexis Antonio Franco Moreno1, Mario Alejandro Bustos Paz3
1From the Hematopoietic Stem Cell Transplantation Unit, Maternal and child department, Fundación Valle del Lili, Cali, Colombia.
Background And Objective:
Hematopoietic stem cell transplantation (HSCT) is a curative treatment but carries a high mortality risk due to infections from immunosuppression. Infections by multidrug-resistant (MDR) pathogens are rising, and rectal screening may predict bacteremia and reduce mortality. This study aims to evaluate the utility of periodic rectal screening in predicting MDR-induced bacteremia by day 100 in pediatric HSCT patients.
Materials And Methods:
A retrospective cohort study was conducted in patients under 18 who underwent rectal screening before HSCT at a high-complexity center between 2018 and 2022. Descriptive analysis and regression models identified risk factors for bacteremia and mortality.
Results:
Two hundred ten HSCT procedures were analyzed. MDR colonization was found in 51.9% of patients, with 18.1% of colonized individuals developing bacteremia. Colonization was a significant risk factor for MDR Gram-negative bacteremia (relative risk ratio 7.25, 95% CI: 1.97-26, P = 0.003), and was associated with higher mortality ( P = 0.034).
Conclusions:
Rectal screening effectively identifies MDR bacterial colonization in pediatric HSCT patients and facilitates targeted empirical antibiotic therapy adjustments, representing a valuable tool for clinical management in this population.
More Related Videos
05:45Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
Published on: April 26, 2019
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018